Hypophosphatemia, Severe Bone Pain, Gait Disturbance, and Fatigue Fractures After Iron Substitution in Inflammatory Bowel Disease: A Case Report

被引:27
作者
Bartko, Johann [1 ]
Roschger, Paul [1 ]
Zandieh, Shahin [1 ,2 ]
Brehm, Attila [1 ]
Zwerina, Jochen [1 ]
Klaushofer, Klaus [1 ]
机构
[1] Hanusch Hosp, Ludwig Boltzmann Inst Osteol, WGKK & AUVA Trauma Ctr Meidling, Dept Med 1, Heinrich Collin Str 30, A-1140 Vienna, Austria
[2] Hanusch Hosp, Inst Radiol & Nucl Med, Vienna, Austria
关键词
HYPOPHOSPHATEMIA; FGF23; IRON INFUSION; OSTEOMALACIA; FRACTURE; CROHN'S DISEASE; INFLAMMATORY BOWEL DISEASE; TUMOR-INDUCED OSTEOMALACIA; MINERALIZATION DENSITY DISTRIBUTION; GROWTH-FACTOR; 23; POSTMENOPAUSAL OSTEOPOROSIS; MATRIX MINERALIZATION; FERRIC CARBOXYMALTOSE; PHOSPHATE HOMEOSTASIS; ZOLEDRONIC ACID; ANEMIA; TRIAL;
D O I
10.1002/jbmr.3319
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Intravenous infusions of different iron formulations are recognized as a cause of hypophosphatemia. Chronic hypophosphatemia can alter bone metabolism and bone material structure. As a consequence, osteomalacia may develop and lead to bone fragility. Herein, we report a patient with Crohn's disease presenting with persistent hypophosphatemia and insufficiency fractures while receiving regular iron infusions due to chronic gastrointestinal bleeding. Previously, the patient regularly received vitamin D and also zoledronic acid. The patient underwent bone biopsy of the iliac crest that showed typical signs of osteomalacia with dramatically increased osteoid volume and decreased bone formation. Analysis of the bone mineralization density distribution (BMDD) revealed a more complex picture: On the one hand, there was a shift to higher matrix mineralization, presumably owing to low bone turnover; on the other hand, a broadening of the BMDD indicating more heterogeneous mineralization due to osteomalacia was also evident. This is the first report on changes of bone histomorphometry and bone matrix mineralization in iron-induced osteomalacia. (c) 2017 American Society for Bone and Mineral Research.
引用
收藏
页码:534 / 539
页数:6
相关论文
共 40 条
[1]   Drug-specific hypophosphatemia and hypersensitivity reactions following different intravenous iron infusions [J].
Bager, Palle ;
Hvas, Christian L. ;
Dahlerup, Jens F. .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 83 (05) :1118-1125
[2]   A randomized, open-label trial of iron isomaltoside 1000 (MonoferA®) compared with iron sucrose (VenoferA®) as maintenance therapy in haemodialysis patients [J].
Bhandari, Sunil ;
Kalra, Philip A. ;
Kothari, Jatin ;
Ambuehl, Patrice M. ;
Christensen, Jeppe H. ;
Essaian, Ashot M. ;
Thomsen, Lars L. ;
Macdougall, Iain C. ;
Coyne, Daniel W. .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2015, 30 (09) :1577-1589
[3]   A Randomized Noninferiority Trial of Intravenous Iron Isomaltoside versus Oral Iron Sulfate in Patients with Nonmyeloid Malignancies and Anemia Receiving Chemotherapy: The PROFOUND Trial [J].
Birgegard, Gunnar ;
Henry, David ;
Glaspy, John ;
Chopra, Rakesh ;
Thomsen, Lars L. ;
Auerbach, Michael .
PHARMACOTHERAPY, 2016, 36 (04) :402-414
[4]   Long-term iron polymaltose infusions associated with hypophosphataemic osteomalacia: a report of two cases and review of the literature [J].
Bishay, Ramy H. ;
Ganda, Kirtan ;
Seibel, Markus J. .
THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM, 2017, 8 (1-2) :14-19
[5]   The clinical contribution of cortical porosity to fragility fractures [J].
Bjornerem, Ashild .
BONEKEY REPORTS, 2016, 5
[6]   68Ga DOTA-TATE PET/CT allows tumor localization in patients with tumor-induced osteomalacia but negative 111In-octreotide SPECT/CT [J].
Breer, Stefan ;
Brunkhorst, Thomas ;
Beil, F. Timo ;
Peldschus, Kersten ;
Heiland, Max ;
Klutmann, Susanne ;
Barvencik, Florian ;
Zustin, Jozef ;
Gratz, Klaus-Friedrich ;
Amling, Michael .
BONE, 2014, 64 :222-227
[7]   Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis [J].
Carbonare, LD ;
Arlot, ME ;
Chavassieux, PM ;
Roux, JP ;
Portero, NR ;
Meunier, PJ .
JOURNAL OF BONE AND MINERAL RESEARCH, 2001, 16 (01) :97-103
[8]   Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia [J].
Carpenter, Thomas O. ;
Imel, Erik A. ;
Ruppe, Mary D. ;
Weber, Thomas J. ;
Klausner, Mark A. ;
Wooddell, Margaret M. ;
Kawakami, Tetsuyoshi ;
Ito, Takahiro ;
Zhang, Xiaoping ;
Humphrey, Jeffrey ;
Insogna, Karl L. ;
Peacock, Munro .
JOURNAL OF CLINICAL INVESTIGATION, 2014, 124 (04) :1587-1597
[9]   Cortical and Trabecular Bone Density in X-Linked Hypophosphatemic Rickets [J].
Cheung, Moira ;
Roschger, Paul ;
Klaushofer, Klaus ;
Veilleux, Louis-Nicolas ;
Roughley, Peter ;
Glorieux, Francis H. ;
Rauch, Frank .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2013, 98 (05) :E954-E961
[10]   Tumor localization and biochemical response to cure in tumor-induced osteomalacia [J].
Chong, William H. ;
Andreopoulou, Panagiota ;
Chen, Clara C. ;
Reynolds, James ;
Guthrie, Lori ;
Kelly, Marilyn ;
Gafni, Rachel I. ;
Bhattacharyya, Nisan ;
Boyce, Alison M. ;
El-Maouche, Diala ;
Crespo, Diana Ovejero ;
Sherry, Richard ;
Chang, Richard ;
Wodajo, Felasfa M. ;
Kletter, Gad B. ;
Dwyer, Andrew ;
Collins, Michael T. .
JOURNAL OF BONE AND MINERAL RESEARCH, 2013, 28 (06) :1386-1398